Article info

Original research
Peripherally-driven myeloid NFkB and IFN/ISG responses predict malignancy risk, survival, and immunotherapy regime in ovarian cancer

Authors

  • Jenny Sprooten Laboratory of Cell Stress & Immunity, Department of Cellular & Molecular Medicine, KU Leuven, Leuven, Belgium PubMed articlesGoogle scholar articles
  • Ann Vankerckhoven Department of Oncology, Leuven Cancer Institute, Laboratory of Tumor Immunology and Immunotherapy, KU Leuven, Leuven, Belgium PubMed articlesGoogle scholar articles
  • Isaure Vanmeerbeek Laboratory of Cell Stress & Immunity, Department of Cellular & Molecular Medicine, KU Leuven, Leuven, Belgium PubMed articlesGoogle scholar articles
  • Daniel M Borras Laboratory of Cell Stress & Immunity, Department of Cellular & Molecular Medicine, KU Leuven, Leuven, Belgium PubMed articlesGoogle scholar articles
  • Yani Berckmans Department of Oncology, Leuven Cancer Institute, Laboratory of Tumor Immunology and Immunotherapy, KU Leuven, Leuven, Belgium PubMed articlesGoogle scholar articles
  • Roxanne Wouters Department of Oncology, Leuven Cancer Institute, Laboratory of Tumor Immunology and Immunotherapy, KU Leuven, Leuven, Belgium PubMed articlesGoogle scholar articles
  • Raquel S Laureano Laboratory of Cell Stress & Immunity, Department of Cellular & Molecular Medicine, KU Leuven, Leuven, Belgium PubMed articlesGoogle scholar articles
  • Thais Baert Department of Oncology, Leuven Cancer Institute, Laboratory of Tumor Immunology and Immunotherapy, KU Leuven, Leuven, BelgiumDepartment of Oncology, Leuven Cancer Institute, Laboratory of Gynaecologic Oncology, KU Leuven, Leuven, Belgium PubMed articlesGoogle scholar articles
  • Louis Boon JJP Biologics, Warsaw, Poland PubMed articlesGoogle scholar articles
  • Chiara Landolfo Department of Oncology, Leuven Cancer Institute, Laboratory of Tumor Immunology and Immunotherapy, KU Leuven, Leuven, BelgiumDepartment of Development and Regeneration, KU Leuven, Leuven, BelgiumQueen Charlotte's and Chelsea Hospital, Imperial College, London, UKDipartimento Scienze della Salute della Donna e del Bambino, Fondazione Policlinico Universitario A. Gemelli, Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy PubMed articlesGoogle scholar articles
  • Antonia Carla Testa Dipartimento Scienze della Salute della Donna e del Bambino, Fondazione Policlinico Universitario A. Gemelli, Istituto di Ricovero e Cura a Carattere Scientifico, Rome, ItalyDipartimento Scienze della Vita e Sanità pubblica, Università Cattolica del Sacro Cuore, Rome, Italy PubMed articlesGoogle scholar articles
  • Daniela Fischerova Charles University, Praha, Czech Republic PubMed articlesGoogle scholar articles
  • Caroline Van Holsbeke Ziekenhuis Oost-Limburg, Genk, Belgium PubMed articlesGoogle scholar articles
  • Tom Bourne Queen Charlotte's and Chelsea Hospital, Imperial College, London, UK PubMed articlesGoogle scholar articles
  • Valentina Chiappa National Cancer Institute of Milan, Milan, Italy PubMed articlesGoogle scholar articles
  • Wouter Froyman Department of Development and Regeneration, KU Leuven, Leuven, BelgiumDepartment of Gynaecology and Obstetrics, UZ Leuven, Leuven, Belgium PubMed articlesGoogle scholar articles
  • Dominique Schols Department of Microbiology, Immunology and Transplantation, Laboratory of Virology and Chemotherapy, Rega Institute, KU Leuven, Leuven, Belgium PubMed articlesGoogle scholar articles
  • Patrizia Agostinis Department of Cellular and Molecular Medicine, Cell Death Research and Therapy Laboratory, KU Leuven, BelgiumVIB Center for Cancer Biology, VIB, Leuven, Belgium PubMed articlesGoogle scholar articles
  • Dirk Timmerman Department of Development and Regeneration, KU Leuven, Leuven, BelgiumDepartment of Gynaecology and Obstetrics, UZ Leuven, Leuven, Belgium PubMed articlesGoogle scholar articles
  • Sabine Tejpar Laboratory for Molecular Digestive Oncology, Department of Oncology, KU Leuven, Leuven, Belgium PubMed articlesGoogle scholar articles
  • Ignace Vergote Department of Oncology, Leuven Cancer Institute, Laboratory of Tumor Immunology and Immunotherapy, KU Leuven, Leuven, BelgiumDepartment of Oncology, Leuven Cancer Institute, Laboratory of Gynaecologic Oncology, KU Leuven, Leuven, BelgiumDepartment of Gynaecology and Obstetrics, UZ Leuven, Leuven, Belgium PubMed articlesGoogle scholar articles
  • An Coosemans Department of Oncology, Leuven Cancer Institute, Laboratory of Tumor Immunology and Immunotherapy, KU Leuven, Leuven, Belgium PubMed articlesGoogle scholar articles
  • Abhishek D Garg Laboratory of Cell Stress & Immunity, Department of Cellular & Molecular Medicine, KU Leuven, Leuven, Belgium PubMed articlesGoogle scholar articles
  1. Correspondence to Professor Abhishek D Garg; abhishek.garg{at}kuleuven.be
View Full Text

Citation

Sprooten J, Vankerckhoven A, Vanmeerbeek I, et al
Peripherally-driven myeloid NFkB and IFN/ISG responses predict malignancy risk, survival, and immunotherapy regime in ovarian cancer

Publication history

  • Accepted October 17, 2021
  • First published November 18, 2021.
Online issue publication 
November 18, 2021

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.